Cannabinoid receptor gene (CNR1): Association with IV drug use

Molecular Psychiatry

Volumn 2, Issue 2, 1997, Pages 161-168

  Comings, D E ^a   Muhleman, D ^a   Gade, R ^a   Johnson, P ^b   Verde, R ^b   Saucier, G ^c   MacMurray, J ^d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Jerry L Pettis VA Hospital   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

Cannabinoid receptor; Dopamine; Drug abuse; Marijuana; Reward

Indexed keywords

AMPHETAMINE; BRAIN RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; COCAINE; MICROSATELLITE DNA;

ADULT; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FACTORIAL ANALYSIS; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR GENE; STATISTICAL ANALYSIS;

EID: 0030946048     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000247     Document Type: Article

References (56)

1. Petersen RE. Marijuana and Health: 8th Annual Report to the US Congress from the Secretary of Health and Human Services. National Institute on Drug Abuse. US Public Health Service: Rockville, MD, 1980.
2. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-1647.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
5. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
6. Hollister LE, Gillespie HK. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. Clin Pharmacol Ther 1973; 14: 353-357.
7. Hilikas JA, Weller RA, Morse C. Effects of regular marijuana use on sexual performance. J Psychoactive Drugs 1982; 14: 59-70.
8. Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995; 35: 607-634.
9. Braff DL, Silverton L, Saccuzzo DP, Janowsky DS. Impaired speed of visual information processing in marijuana intoxication. Am J Psychiatry 1981; 138: 613-617.
10. Miller LL. Cannabis and the brain with special reference to the limbic system. In: Nahas GG, Paton WDM (eds). Marihuana Biological Effects. Pergamon Press: New York, 1979, pp 539-566.
11. Miller LL. Marijuana: acute affects on human memory. In. Agurell S, Dewey WL, Willette RE (eds). The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects. Academic Press: New York, 1984, pp 21-46.
12. Pope HG Jr, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996; 275: 521-527.
13. Zeltser R, Seltzer Z, Eisen A, Feigenbaum JJ, Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain 1991; 47: 95-103.
14. Hershkowitz M, Goldman R, Raz A. Effect of cannabinoids on neutrotransmitter uptake ATPase activity and morphology of mouse brain synaptosomes. Biochem Pharmacol 1977; 26: 1327-1331.
15. Banerjee SP, Snyder SH, Mechulam R. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther 1975; 194: 74-81.
16. Johnson KM, Dewey WL, Harris LS. Some structural requirement for inhibition of high-affinity synaptosomal serotonin uptake by cannabinoids. Mol Pharmacol 1976; 12: 345-352.
17. Devane WA. New dawn of cannabinoid pharmacology. Trends Pharmacol Sci 1994; 15: 40-41.
18. Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 1993; 44: 498-503.
19. Chiders SR, Fleming L, Marckel D, Pacheco M, Sexton T, Ward S. Opioid and cannabinoid receptor inhibition of adenyl cyclase in brain. Ann NY Acad Sci 1992; 654: 33-51.
20. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann NY Acad Sci 1992; 654: 19-32.
21. Devane WA, Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 1994; 91: 6698-6701.
22. Mailleux P, Vanderhaeghen JJ. Dopaminergic regulation of cannabinoid receptor: mRNA levels in the rat caudateputamen: an in situ hybridization study. J Neurochemistry 1993; 61: 1705-1712.
23. Romero J, Garcia L, Cebeira G, Zadrozny D, Fernández-Ruiz JJ, Ramos JA. The endogenous cannabinoid receptor ligand, anadamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci 1995; 56: 2033-2040.
24. Mailleaux P, Vanderhaeghen JJ. Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hybridization study. Neurosci Lett 1993; 156: 51-53.
25. Mailleux P, Vanderhaeghen J. Glutamatergic regulation of cannabinoid receptor gene expression in the caudateputamen. Eur J Pharmacology 1994; 266: 193-196.
26. DiChiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-5278.
27. Koob GF. Drug of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992; 13: 177-184.
28. Blum K, Cull JG, Braverman ER, Comings DE. Reward Deficiency Syndrome. Am Scient 1996; 84: 132-145.
29. 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 1995; 56: 2073-2080.
30. Spandidos DA, Holmes L. Transcriptional enhancer activity in the variable tandem repeat DNA sequence downstream of the human Ha-ras-1 gene. FEBS Lett 1987; 218: 41-46.
31. 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 1990; 102: 156-162.
32. DiChiara GD, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13: 185-193.
33. Musty RE, Kaback L. Relationships between motivation and depression in chronic marijuana users. Life Sci 1995; 56: 2151-2158.
34. Dawson E. Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiat Genet 1995; 5: S50.
35. Davis LL, Hurt RD, Morse RM, O'Brien PC. Discriminant analysis of the self-administered alcoholism screening test. Alcoholism: Clin Exp Res 1987; 11: 269-273.
36. Robins LN, Heizer J, Croughan J, Ratclif KS. National Institute of Health diagnostic interview schedule. Arch Gen Psychiatry 1981; 38: 381-389.
37. Hodgins DC, Guebaly N. More data on the Addiction Severity Index. Reliability and validity with the mentally ill substance abuser. J Nerv Ment Dis 1992; 180: 197-201.
38. Roff DA, Bentzen P. The statistical analysis of mitochondrial DNA polymorphisms: chi square and the problem of small samples. Biol Evol 1989; 6: 539-543.
39. Comings DE. Polygenetic inheritance of psychiatric disorders. In: Blum K, Noble EP, Sparks RS, Sheridan PJ (eds). Handbook of Psychiatric Genetics. CRC Press: Boca Raton, FL, 1996, pp 235-260.
40. Comings DE. Polygenic inheritance and minisatellites. Psychiat Genet 1996; 6: 157-158.
41. Comings DE. Polygenic inheritance and micro/minisatellites. (submitted).
42. Hamada H, Petrino MG, Kakunaga T. A novel repeated element with Z-DNA-forming potential is widely found in evolutionarily diverse eukaryotic genomes. Proc Natl Acad Sci USA 1982; 79: 6465-6469.
43. Schroth GP, Chou P-J, Ho PS. Mapping Z-DNA in the human genome. J Biol Chem 1992; 267: 11846-11855.
44. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol 1989; 40: 191-225.
45. 9-tetrahydrocannabinol. Psychopharmacology (Berl) 1988; 96: 142-144.
46. Self DW, Stein L. Receptor subtypes in opioid and stimulant reward. Pharmacol Toxicol 1992; 70: 87-94.
47. O'Hara BF, Smith SS, Bird G, Persico AM, Suarez B, Cutting GR, Uhl GR. Dopamine D2 receptor RFLPs, haplo-types and their association with substance use in Black and Caucasian research volunteers. Hum Genet 1993; 43: 209-218.
48. Smith SS, O'Hara BF, Persico AM, Gorelick DA, Newlin DB, Vlahov D, Solomon L, Pickins R, Uhl GR. Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch Gen Psychiatry 1992; 49: 723-727.
49. 2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend 1993; 33: 271-285.
50. Comings DE, Muhleman D, Ahn C, Gysin R, Flanagan SD. The dopamine D2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend 1994; 34: 175-180.
51. Self DW, Barnhart WJ, Lehrman DA, Nestler EJ. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 1996; 271: 1586-1589.
52. Polick J, Pollock VE, Bloom FE. Meta-analysis of P300 amplitude from males at risk for alcoholism. Psychol Bull 1994; 115: 55-73.
53. Hill SY, Muka D, Steinhauer S, Locke J. P300 amplitude decrements in children from families of alcoholic female probands. Biol Psychiatry 1995; 38: 622-632.
54. Cohen HL, Wang W, Porjesz B, Begleiter H. Auditory P300 in young alcoholics: regional response characteristics. Alcohol Clin Exp Res 1995; 19: 469-475.
55. Brigham J, Hering RI, Moss HB. Event-related potentials and alpha synchronization in preadolescent boys at risk for psychoactive substance use. Biol Psychiatry 1995; 37: 834-846.
56. Johnson JP, Muhleman D, MacMurray J, Gade R, Verde R, Ask M, Kelley J, Comings DE. Association between the cannabinoid receptor gene (CNR1), and the P300 wave of event-related potentials, and drug dependence. Mol Psychiatry 1997; 2: 169-171.